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Abstract
Introduction. Runx1, a Runt domain transcription factor, controls the differentiation of nociceptors that express the
neurotrophin receptor Ret, regulates the expression of many ion channels and receptors, and controls the lamina-speciﬁc
innervation pattern of nociceptive afferents in the spinal cord. Moreover, mice lacking Runx1 exhibit speciﬁc defects in thermal
and neuropathic pain. We investigated whether conditional activation of Runx1 short isoform (Runx1a), which lacks a
transcription activation domain, inﬂuences differentiation of neural crest stem cells (NCSCs) in vitro and in vivo during
development and whether postnatal Runx1a activation affects the sensitivity to neuropathic pain.
Methods. We activated ectopic expression of Runx1a in cultured NCSCs using the Tet-ON gene regulatory system during the
formation of neurospheres and analyzed the proportion of neurons and glial cells originating from NCSCs. In in vivo
experiments we applied doxycycline (DOX) to pregnant mice (days 8–11), i.e. when NCSCs actively migrate, and examined
the phenotype of offsprings. We also examined whether DOX-induced activation of Runx1a in adult mice affects their
sensitivity to mechanical stimulation following a constriction injury of the sciatic nerve.
Results. Ectopic Runx1a expression in cultured NCSCs resulted in predominantly glial differentiation. Offsprings in which
Runx1a had been activated showed retarded growth and displayed megacolon, pigment defects, and dystrophic dorsal
root ganglia. In the neuropathic pain model, the threshold for mechanical sensitivity was markedly increased following
activation of Runx1a.
Conclusion. These data suggest that Runx1a has a speciﬁc role in NCSC development and that modulation of Runx1a activity
may reduce mechanical hypersensitivity associated with neuropathic pain.
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Dorsal root ganglia (DRGs) are composed of subsets
of anatomically and functionally specialized sensory
neurons and glial cells, which like all other neurons
and glial cells of the peripheral nervous system are
derived from the neural crest. The development of
these cell populations is regulated by sequential
expression of alimited numberof transcription factors
in concert with environmental components. Runt
domain transcription factor signaling plays a key
role in sensory neuron speciﬁcation. Thus Runx3
acts to diversify an Ngn1-independent neuronal
cohort by promoting the differentiation of proprio-
ceptive sensory neurons, whereas Runx1 controls
neuronal diversiﬁcation within Ngn1-dependent
TrkA
+ neurons by repression of the neuropeptide
Calcitonin gene-related peptide (CGRP)-expressing
phenotype and induction of a Ret-expressing pheno-
type (1–3). The Runx1 locus generates a number of
splice isoforms which may play different speciﬁc roles
in cell differentiation (4). The short Runx1 isoform
(Runx1a) has a strong afﬁnity for binding to the DNA
consensus sequence which is common for all types of
Runx proteins but lacks a transactivation domain.
Runx1a is therefore commonly viewed as a functional
inhibitor of the Runx1 long isoform (Runx1b). How-
ever, Runx1a may also have speciﬁc effects of its own,
as evidenced by its ability to transactivate the inter-
leukin-3 promoter (5) and enhance engraftment
capacity of hematopoietic progenitor cells (6).
Here, we have examined the role of Runx1a in
differentiation of neural crest stem cells (NCSCs)
in vitro and in vivo and in the development of neuro-
pathic pain behavior in adult mice. For this purpose we
have employed the Tet system (7) to conditionally
activate Runx1a in Rosa26 or Sox10-expressing cells.
AsasourceofNCSCs we usedcellsfrom the boundary
cap of Rosa26-rtTA/TRE-Runx1 or Sox10-rtTA/
TRE-Runx1 transgenic mice. The boundary cap con-
tains a population of multipotent neural crest stem
cells, which are able to differentiate to sensory neurons
and to Schwann cells in vitro (8) and in vivo after
transplantation (9,10). The activation of Runx1a was
accompanied by the expression of enhanced green
ﬂuorescent protein (EGFP), which was activated
throughtheinternalribosomeentrysite(IRES)-EGFP.
Material and methods
Generation of transgenic mice
The tetracycline-inducible Runx1a (short isoform)-
EGFP mouse was generated. At the core of the
bi-partite regulatable system in this mouse is a reverse
tetracycline transactivator (rtTA) which after binding
tetracycline/doxycycline becomes capable of interact-
ing with the tetracycline-responsive element (TRE).
This interaction results in up-regulation of a Runx1a
cDNA and subsequent IRES-EGFP expression.
RtTA was targeted into the ubiquitously expressed
Rosa26 locus, or Sox10 locus, and Runx1a-IRES-
EGFP cDNA driven by the tetracycline-responsive
element (TRE) targeted upstream the hypoxanthine
phosphoribosyltransferase (HPRT) locus. By breed-
ing Rosa26-rtTA or Sox10-rtTA mice with TRE-
Runx1a mice, two strains of mice were obtained:
Rosa26-rtTA/EGFP-TRE-Runx1a and Sox10-rtTA/
EGFP-TRE-Runx1a.
Animals and genotyping
All procedures were approved by the Regional
Ethics Committee for Research on Animals and car-
ried out according to the guidelines of the Society for
Neuroscience.
To explore the effect of ectopic Runx1a expression
during development we used new-born double
transgenic Sox10-rtTA/TRE-Runx1a mice, which
were obtained by breeding Sox10-rtTA2
S-M2 mice
with HPRT-Runx1a-IRES-EGFP mice. Doxycycline
(DOX) was given to the pregnant dam between days 8
and 11 of pregnancy. The offsprings were genotyped
individually after birth, and double transgenic pups
were compared with non-transgenic ones from the
same litter.
For in vitro experiments and for in vivo experiments
in a neuropathic pain model we used Rosa26-rtTA/
HPRT-Runx1a-IRES-EGFP mice. All mice were
homozygous for the Rosa26-rtTA gene and differed
only in the presence of the TRE-Runx1a gene. For the
neuropathic pain experiments we used three groups of
double transgenic mice: 1) without injury as a control
group, 2) with injury but without DOX-activated
Runx1a expression as a second control group, and
3) with injury and with DOX-activated Runx1a
expression. For the in vitro experiments we used
DOX-activated and non-activated neurospheres
obtained from double transgenic mice Rosa26-
rtTA/TRE-Runx1a.
Sox10-rtTA2
S-M2 mice, which contain a second
generation reverse tetracycline-controlled transactiva-
tor (rtTA2
S-M2) knocked-into the genomic Sox10
locus, have been previously described along with
protocols for their genotyping (11). Rosa26-rtTA/
TRE-Runx1a male and female mice were genotyped
before breeding. Each individual embryo from which
we collected DRGs for stem cell cultures was also
genotyped.
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Sox10-rtTA (9), were designed to speciﬁc parts of the
different transgenic constructs.
Rosa26-rtTA/HPRT-Runx1a-IRES-EGFP mice
Culture of boundary cap neural crest stem cells
(bNCSCs)
Dorsal root ganglia (DRGs) were isolated from
11-day-old embryos (E11) and used for setting up
bNCSC cultures (8). The medium was changed every
other day before neurospheres began to form after
about 3 weeks of culture.
Differentiation assay
After the neurospheres were formed, they were dis-
sociated to single cells and divided into two groups,
and to one of them DOX (5 mg/mL) was added every
third day during the formation of new neurospheres.
Under DOX treatment EGFP-expressing neuro-
spheres were formed. Newly formed DOX-treated
EGFP-expressing neurospheres and DOX-untreated
neurospheres were plated on poly-D-Lysine (PDL)
(50 mg/mL) and laminin (20 mg/mL) and maintained
in DMEM-F12/Neurobasal medium supplemented
with N2 1:200, B27 1:100, 0.1 mM non-essential
amino acids, and 2 mM sodium pyruvate. The
medium was replenished every third day. DOX was
continuously added to DOX-treated wells every third
day, when medium was changed.
Assessment of NCSC cultures and immunocytochemistry
The cultures were ﬁxed at 48 hours, 1 week, and
2 weeks after DOX treatment was started. Just before
cultures were ﬁxed, we examined whether EGFP was
expressed in the cultured cells in an inverted ﬂuores-
cence microscope (Nikon) and photographed cells in
phase contrast and in green band pass ﬁlter. There-
after the medium was removed, cells washed with
PBS and ﬁxed in 0.15 M phosphate-buffered 4%
formaldehyde (v/v), 14% saturated picric acid (v/v)
for 10 minutes. Before immunocytochemical proces-
sing the ﬁxed slides were analyzed in the ﬂuorescent
microscope again, and the complete disappearance of
Tet-regulated expression of EGFP was conﬁrmed.
This was important for the possibility to use FITC
and Cy2 conjugated secondary antibodies for the
subsequent immunocytochemical labeling. After ﬁx-
ation cells were washed carefully in cold PBS for
30 minutes and pre-incubation solution added
directly to the wells with the cover-slips for 1 hour.
Slides were incubated with primary antibodies
against bTUB (mouse monoclonal, 1:500; Covance
cat#MMS-435P), GFAP (rabbit polyclonal, 1:1000;
DAKO cat#Z0334), nestin (mouse monoclonal,
1:500; Immunkemi; cat#VP-N752), Sox10 (poly-
clonal guinea-pig, 1:1000; M. Wegner, Erlangen),
Mts1/S100A4 (rabbit polyclonal, 1:700; gift from
Dr Lukanidin), S100 beta (mouse monoclonal,
1:250; Sigma cat#S2532) at 8oC overnight. After
rinsing, appropriate secondary antibodies (Jackson
ImmunoResearch) were applied: Cy3 conjugated
donkey anti-mouse (1:500), Cy2-conjugated donkey
anti-rabbit, Cy3-conjugated donkey anti-guinea-pig,
and AMCA-conjugated donkey anti-rabbit (1:100).
Cover-slips were mounted in 50% glycerol in PBS
containing 100 mM propyl-gallate to prevent photo-
bleaching. As negative control secondary antibodies
were added to the cells without prior incubation with
the primary antibodies.
For labeling of whole neurospheres, these were
carefully moved directly from the well-dish to the
ﬁxative and subsequently processed for labeling as
described above. FITC-conjugated donkey anti-
rabbit (1:100) antibodies were used in combination
with Hoechst 33342 nuclear labeling (11 ng/mL;
Molecular Probes, Eugene, OR).
Activation of Runx1a expression in development and
analysis of offspring phenotype
DOX was applied in the drinking water (3 g/L with
50 g/L sucrose) to the pregnant females with
Rosa26-rtTA/TRE-Runx1a or Sox10-rtTA/TRE-
Runx1a background during embryonic days 8–11.
The pups were examined daily after birth, and
post-mortem tissue from spinal cord and DRGs
removed and immersion-ﬁxed in 0.15 M phos-
phate-buffered 4% formaldehyde (v/v), 14% saturated
picric acid (v/v) for 4 hours. After ﬁxation, tissue was
immersed in PBS containing 15% sucrose for cryo-
protection overnight. Sections were cut at 12 mmo na
cryostat and labeled with antibodies to beta-tubulin
(bTUB), peripherin, and glial ﬁbrillary acidic protein
(GFAP), as described above.
Microscopic analysis of cultures
Immunolabeled material was examined in a Nikon
Eclipse E800 microscope equipped with ﬁlters for
separate or combined viewing of red, green, and
blue ﬂuorescence. For photography, a Nikon
DXM1200F digital camera system was used. The
number of cells labeled with glial ﬁbrillary acidic
protein (GFAP) and beta-tubulin (bTUB) was
58 N. Kanaykina et al.counted in ten optical ﬁelds after 2 weeks in cultures
from six experiments from each group.
Neuropathic pain model and behavioral assessment
Surgery. The surgical procedure was based on that
described by Bennett and Xie (12,13). Twelve mice
harboring in their genome the transgenes ROSA-rtTA
and HPRT-TRE-RUNX1a-IRES-eGFP were anes-
thetized with isoﬂurane 2.5%–3% delivered in pure
oxygen. Body temperature was continuously moni-
tored and maintained at 37.5C during the surgery.
A small incision was made medially in the thigh of the
right hind leg to expose the sciatic nerve. The nerve
was gently separated from adjacent blood vessels and
loosely constricted with three ligations, using 6-0
polyﬁber suture material. Half of the 12 mice sub-
jected to the chronic constriction injury at the sciatic
nerve received doxycycline (DOX) solution in their
drinking water. The other half received the injury but
not the DOX treatment. In addition, a control group
was included of six non-operated animals that
received DOX treatment.
Behavioral testing. The animals’ responsiveness and
sensitivity to tactile stimulation was assessed 14 days
after ligation. Mice were placed in a transparent
plastic cage equipped with a mesh bottom, which
guaranteed easy access to the paws. Prior to testing,
each mouse was allowed to acclimatize to the cage for
30 min. A series of calibrated von Frey ﬁlament
(Semmes Weinstein Monoﬁlaments; Soeling, Wood
Dale, IL, USA) was used to determine the 50%
likelihood of a paw withdrawal response (50% thresh-
old) using the up-and-down method of Dixon (14).
Nine von Frey ﬁlaments were used with bending
forces equivalent to 0.02, 0.04, 0.07, 0.16, 0.4, 0.6,
1.4, and 2.0 g. According to the Dixon paradigm,
testing was initiated with the 0.4-g hair, located in the
middle of the series. Each stimulus was applied
perpendicularly to the plantar surface of the right
hind paw with sufﬁcient force to bend the ﬁlament
for 5–6 seconds. If paw withdrawal was not observed
as a response to the initial hair stimulus, a stronger
(i.e. heavier) stimulus was given. On the other hand, if
the initial stimulus elicited a paw withdrawal, the next
weaker (i.e. weaker) stimulus was chosen. This pro-
cedure was carried out until ﬁve measurements were
obtained following an initial behavioral change, or
until ﬁve negative (score 0.02 g) or ﬁve positive scores
(score of 2.0 g) were obtained. The resulting patterns
of positive and negative responses were tabulated
using the convention, X = withdrawal; 0 = no with-
drawal (see Table I), and the 50% response threshold
was interpolated using the formula (15): 50% g
threshold = (10^[Xf+kd]), where Xf = value (in log
units) of the ﬁnal von Frey hair used; k = tabular value
for the pattern of positive/negative responses; and
d=mean difference (in log units) between stimuli
(here, 0.25).
Statistics
Statistical analyses were performed using GraphPad
Prism 5.0. D’Agostino and Pearson omnibus normal-
ity test was used to determine whether data followed a
Gaussian distribution. Kruskal-Wallis test was used to
test whether there were any overall differences related
to treatments, followed by Dunn’s post-test to com-
pare differences between groups. P-values less than
0.05 were considered signiﬁcant.
Results
DOX-activated ectopic expression of Runx1a
induces predominantly glial differentiation in cul-
tured NCSCs
Table I. Genotyping of transgenic mice.
OLIGO name start len tm gc% any 3’ seq
Runx1-F 694 20 59.99 55.00 7.00 3.00 AACCCTCAGCCTCAGAGTCA
IRES-R 993 20 59.99 50.00 7.00 2.00 AGGAACTGCTTCCTTCACGA
Product size: 300.
Runx1a IRES EGFP TRE
Figure 1. Genotyping strategy. The forward primer is located in human Runx1a, the reverse primer binds to the IRES sequence.
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spheres were formed (Figure 2A). DOX-treated
EGFP-expressing neurospheres as well as DOX-
untreated EGFP-negative neurospheres (Figure 2B)
were placed on differentiation assay for 48 hours,
1 week, and 2 weeks. DOX treatment was continued
in previously DOX-treated cultures. After 48 hours
the neurospheres had attached to the PDL/laminin-
coated cover-slips and were taken for immunocyto-
chemical analysis. bTUB and GFAP-expressing cells
extensively migrated from the explants. In DOX-
treated cultures most of the differentiated cells
expressed the glial marker GFAP (Figure 2C),
whereas in untreated cultures numerous differenti-
ated cells expressing bTUB were found in addition to
GFAP-positive ones (Figure 2D).
After 1 week in differentiation assay the morphol-
ogy of DOX-treated and DOX-untreated cultures was
different (Figure 2E and F). In DOX-treated cultures
the majority of cells had elongated shapes resembling
glial cells (Figure 2E), whereas in DOX-untreated
cultures many cells resembled neurons (Figure 2F).
The EGFP-labeling in live cultures was exclusively
associated with elongated glia-like cells only in DOX-
treated cultures (Figure 2G–I).
Two weeks after differentiation assay, cultures
were ﬁxed and labeled for GFAP and bTUB
(Figure 3A–D). The proportion of GFAP or bTUB-
labeled cells was counted (Figure 3E and F). The
majority of DOX-treated bNCSCs differentiated to a
glial phenotype (around 90% of the total number of
cells), whereas untreated NCSCs differentiated to
neurons and glial cells with around 50% of each type.
To further verify the identity of glial cells in the
DOX-treated cultures some cover-slips were taken for
immunocytochemical labeling with antibodies to
Sox10 and to the calcium-binding proteins Mts1/
S100A4 and S100-beta. All these glial markers
were expressed in DOX-treated cultures (Figure 4).
DOX-induced ectopic expression of Runx1a in
Sox10-rtTA/TRE-Runx1a embryos results in retarded
fetal growth, pigment defects, megacolon, and dystrophic
DRGs
The size of the litters was reduced in DOX-activated
Sox10-rtTA/TRE-Runx1a animals. The new-born
pups in these litters were unusually small and dis-
played pigment defects (Figure 5A). Genotyping of
the litters conﬁrmed that morphological changes
were manifest only in animals with dual transgenic
background. These pups died after 2–3 days, pre-
sumably from gastrointestinal dysfunction, since
they displayed megacolon at autopsy (Figure 5B).
Microscopic analysis of immunolabeled sections
from spinal cord and DRG of these pups revealed
reduced sizes of DRGs (Figure 5C and D).
DOX-induced expression of Runx1a reduces mechanical
hypersensitivity in a neuropathic pain model
The 50% withdrawal thresholds 14 days after surgery
for each group are shown in Figure 6. All animals in
the injured DOX-untreated group had a considerable
increased hypersensitivity to the von Frey ﬁlament
stimulation (50% threshold: 0.087 ± 0.029 g
(mean ± SEM)), compared to the injured DOX-
treated group (50% threshold: 0.46 ± 0.18 g) as
well as to the non-operated group that received
DOX (50% threshold: 0.40 ± 0.12 g).
However, due to large variations in data from the
injured DOX group and the control group the differ-
ences were not statistically signiﬁcant (Kruskal-Wallis
statistic 5.32; P-value = 0.07).
Discussion
We show that conditional activation of Runx1a in
NCSCs has a powerful impact on NCSC differenti-
ation in vitro and on embryonic development. Fur-
thermore, postnatal activation of Runx1a inﬂuences
the functional properties of mature injured sensory
neurons.
In development of sensory ganglia Runx1 signaling
is necessary ﬁrst for survival of TrkA
+ immature DRG
neurons (2) and later for their diversiﬁcation to non-
peptidergic, Ret
+ nociceptive, and thermoceptive sen-
sory neurons (16). In our recent studies we observed a
reduction in the numbers ofnon-differentiated cells in
DOX-treated transplants (9), suggesting that Runx1
over-expression is sufﬁcient to drive initial differen-
tiation of NCSCs, but not neurogenesis per se (2).
Runx1a is able to block long Runx1 isoform activity
presumably via a dominant-negative mechanism,
since it has a DNA binding but not transactivation
capacity (17). Previously it has been shown that
differentiation of glial cells from Sox10 lacZ hetero-
zygous mice is limited (18). However, after activation
of Runx1a in bNCSCs we noted predominant differ-
entiation along the glial lineage. The reduction of
neuronal differentiation could therefore be explained
as a consequence of Runx1a-mediated functional
inhibition of Runx1 activity. We suggest that the
predominant differentiation of glial cells in our experi-
ments may be a default mechanism at the point
where neuronal and glial lineage speciﬁcations occur.
The observed activation of the reporter gene EGFP
60 N. Kanaykina et al.speciﬁcally in glial cells suggests that Runx1 has a
speciﬁc role in NCSCs differentiation. The possibility
that Runx1a has effects of its own in NCSC devel-
opment is supported by previous data. Runx1a was
shown to transactivate the human interleukin-3 pro-
moter, albeit with less efﬁciency than Runx1b (long
isoform) (5). This transactivation appeared to occur
at a speciﬁc consensus Runx1 binding site
(TGTGGT) located on the DNAse I footprint region
of the human interleukin-3 promoter and a sequence
similar to the consensus binding site (TGTGGG)
located in the footprint region B. Furthermore, trans-
fection of primitive murine or human hematopoietic
cells with Runx1a markedly enhanced their engraft-
ment potential compared to cells transfected with
Runx1b (6).
Thus, our ﬁndings suggest that Runx1a exerts
speciﬁc effects on developing NCSCs and may
A. B.
C. D.
E. F.
G. H. I.
Figure 2. Newly formed neurospheres under doxycycline (DOX) treatment (A) and without DOX (B). Neurospheres 48 hours after removal
of mitogens under DOX treatment (C) or without DOX (D). Numerous GFAP
+ cells (green), but almost no bTUB
+ cells (red) are present in
DOX-treated neurospheres (C), whereas in untreated neurospheres numerous bTUB
+ (red) and some GFAP
+ (green) cells are present (D).
Blue = Hoechst nuclear labeling. Culture of NCSCs after 1 week in differentiation assay. E and F: phase contrast of DOX-treated (E) and
untreated (F) cultures. G–I = attached EGFP
+ cells with glial type morphologies. Scale bar = 100 mm (A, B); 50 mm( C –I). D with permission
from Lippincott Williams & Wilkins.
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in vitro. The divergent properties of Runx1 isoforms,
as well as their co-operation with different co-factors,
therefore endow the Runx1 locus with complex reg-
ulatory effects on NCSC development and function.
Whether this effect of Runx1a has a speciﬁc role
during in vivo development and speciﬁcally in differ-
entiation of glial cells remains to be determined.
DOX-induced activation of Runx1a in Sox10-
rtTA/TRE-Runx1a embryos resulted in offspring of
smaller size than normal litter-mates, and with early
postnatal lethality, cutaneous pigmentation defects,
megacolon, and reduced DRG size. The genotyping
of pups conﬁrmed that these defects were present only
in double transgenic mice. These phenotypic char-
acteristics suggest that ectopic transitory activation of
Runx1a speciﬁcally in Sox10-expressing cells strongly
interferes with normal NCSC migration and probably
also their normal differentiation. These pilot in vivo
experiments did not include the analysis of embryos at
E9.5–E10 when neural crest cells are migrating. Such
analysis could show if fewer cells delaminate from the
neural tube in transgenic compared to wild-type mice.
We can only suggest that the phenotype of the trans-
genic pups is a consequence of Runx1a activity, since
Runx1a was induced speciﬁcally in Sox10-expressing
E.
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Figure 3. Culture of NCSCs 1 week after removal of mitogens. Doxycycline (DOX)-treated (A, C) or untreated (B, D) cultures display a
striking difference in neuronal/glial relationship. In DOX-treated cultures there is an abundance of GFAP
+ cells, and only few bTUB
+ cells,
whereas in untreated cultures GFAP
+ and bTUB
+ cells are both abundant. This situation is veriﬁed by the quantitative analysis of the number
of GFAP
+ and bTUB
+ cells in DOX-treated and untreated cultures (E, F). Scale bar = 50 mm( A –D).
A. B. C.
Figure 4. Immunocytochemistry of DOX-treated cultures, showing labeling with the glial cell markers Mts1/S100A4 (green) as well as
Sox10 (red). Scale bar = 25 mm( A –C).
62 N. Kanaykina et al.cells during days 8–11, i.e. when NCSCs are actively
migrating, and since the phenotypic changes were
only observed in double transgenic Sox10-rtTA/
TRE-Runx1a pups.
It was shown previously that the Sox10-rtTA het-
erozygous mice also display pigmentation abnormal-
ities and megacolon although at much lower
frequency and of less severity. The few Sox10-rtTA
that died of megacolon usually died at the time of
weaning (19), and not as early as in the present study.
Runx1 is expressed in a subpopulation of mature
nociceptor neurons and has been implicated in the
emergence of injury-induced neuropathic pain behav-
ior (18). We therefore addressed the issue whether
activation of Runx1a in adult mice would attenuate
hypersensitivity to mechanical stimulation 2 weeks
following a sciatic nerve chronic constriction injury
(CCI), a well established model of neuropathic pain
behavior (12,13).
We treated control (non-operated) animals with
DOX to ensure that DOX per se did not have any
adverse effect on the animals or on the test results. In
the CCI-operated animals not treated with DOX, we
observed hypersensitivity to mechanical stimulation
of the hind paw. In operated animals receiving DOX,
on the other hand, the withdrawal threshold was
similar to that of non-operated animals. This obser-
vation suggests that activation of Runx1a with DOX
inhibits the activity of Runx1 long isoform activity,
which, in turn, attenuates the development of
CCI-induced neuropathic pain behavior.
The mechanisms underlying neuropathic pain fol-
lowing peripheral nerve injury involve numerous
mediators and signaling systems (20), only some of
which appear to be regulated by Runx1 (18). Previ-
ously it has been shown (16) that Runx1-/- mice do
not develop mechanical allodynia in a neuropathic
pain model, suggesting that Runx1 function is
A.
B.
C.
D.
Figure 5. Comparison between new-born normal mice and new-born mice in which Runx1a expression was activated during embryonic
days 8–11. Note the small body size and pigment defects (A, right), megacolon (B, left), and small DRG size (D compared to C) following
Runx1a activation. DRGs are labeled with the neuronal markers beta-tubulin (green) and peripherin (red). Scale bar = 100 mm (C, D).
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Figure 6. Sensitivity to von Frey ﬁlament stimulation of the hind
paw assessed with the 50% withdrawal threshold in grams 14 days
after a chronic constriction injury of the ipsilateral sciatic nerve.
Runx1a and neural crest stem cell differentiation 63necessary for the manifestation of neuropathic pain
responses. In our experiments after activation of
Runx1a short isoform, the response to mechanical
stimulation was similar to that previously described in
Runx1-/- mice (16). These ﬁndings suggest that mod-
ulation of Runx1 activity with Runx1a or with Runx1
siRNA deserves further investigation as a potential
treatment strategy for nerve injury-induced neuro-
pathic pain.
Since our ﬁndings in the in vitro experiments indi-
cate that Runx1a has effects of its own, postnatal
activation of Runx1a may not act as just a functional
inhibitor of Runx1 long isoform activity. Neverthe-
less, our results suggest that further studies are war-
ranted to determine whether modifying Runx1
activity confers some protection against the develop-
ment of injury-induced neuropathic pain behavior
and whether Runx1a affects glial differentiation
during in vivo development.
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